Maddox Patt, now 27, was diagnosed with plaque psoriasis at age 12 and experienced an emotional toll as a teenager. The chronic autoimmune condition, which causes thick patches on the skin, began to develop when Patt was nicked by a rock and spread throughout his life. Patt, who now works as an account manager, often hid his condition to hide it, which also affected his fashion choices. Eventually, Patt was introduced to ICOTYDE, an oral peptide medication used to treat moderate-to-severe plaque psorsoriasis, and joined a clinical trial. The FDA approved the first-ever oral option for the condition on March 18. Patt credits joining the clinical trial for ICOTDE as a crucial step forward in his battle against the disease.